Terns Pharmaceuticals(US:TERN)2026-03-11 14:02Summary of Terns Pharmaceuticals Conference Call Company Overview - Terns Pharmaceuticals, founded in 2017, focuses on precision oncology, specifically developing small molecule TERN-701 for chronic myeloid leukemia (CML) [3][4] - TERN-701 has shown unprecedented efficacy, demonstrating 2-3 times the efficacy compared to other agents with a differentiated safety profile [3][12] Industry Context - The chronic myeloid leukemia (CML) market has a significant unmet need, particularly in patients who do not achieve major molecular response (MMR) [5][4] - Current treatments, including imatinib and asciminib, have limitations, with over 75% of patients not responding adequately to the best available therapies [5][6] Key Findings from Recent Data - TERN-701 achieved a 75% MMR in patients at doses of 320 mg and above, with deep molecular response rates exceeding 30% [11][12] - The safety profile of TERN-701 is favorable, with low rates of cytopenias and no significant adverse events compared to asciminib [12][13] - TERN-701 has shown efficacy in asciminib-refractory patients, a critical indicator of its potential superiority [15][27] Competitive Landscape - Asciminib has gained approximately 25% market share in the frontline setting, with expectations to reach 50% [6][7] - TERN-701 is positioned as a potential best-in-disease drug due to its efficacy, safety, and lack of food effect, which is crucial for patient adherence [27][40] - The company anticipates that TERN-701 will outperform asciminib in frontline settings, where newly diagnosed patients are generally easier to treat [32][40] Development Plans - Terns Pharmaceuticals plans to conduct a registrational study for TERN-701 in a second-line plus population, with a control arm of a physician's choice 2GTKI [84][86] - A frontline study is also planned, potentially comparing TERN-701 against imatinib or asciminib [86][88] - The company aims to finalize dose selection and engage with the FDA for guidance on study design by mid-2026 [43][82] Financial Position - Terns Pharmaceuticals has secured funding that positions it well for commercialization and launch of TERN-701 in the second-line plus setting [93][94] Additional Insights - The absence of a food effect with TERN-701 is a significant advantage, as many patients struggle with dietary restrictions associated with other therapies [49][55] - The company is exploring a mutation-specific cohort in its studies to address patients with specific genetic mutations, such as T315I [66][72] Conclusion - Terns Pharmaceuticals is poised to make a significant impact in the CML treatment landscape with TERN-701, addressing critical unmet needs and positioning itself against established therapies like asciminib and imatinib. The upcoming studies and FDA interactions will be pivotal in shaping the future of TERN-701 in the market [40][93]